Lekshmi R Nath

Biography:

Dr Lekshmi R. Nath is working as an Associate Professor in the Department of Pharmacognosy at Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, India. She pursued her PhD . under Dr Ruby John Anto, Cancer Research Program, Rajiv Gandhi Centre for Biotechnology (RGCB), Trivandrum, Kerala, an autonomous Research Institution under DBT, Govt: of India. Her Ph.D. findings on hepatocellular carcinoma recently received four international patents US, Canada, Japan & South Korea (WO 2017208254 A1, “Uttroside B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma”). The USFDA has recently granted an Orphan drug designation to the small molecule chemotherapeutic Uttroside–B against hepatocellular carcinoma. MOU signed by RGCB with Oklahoma Medical Research Foundation, USA, for the clinical translation of Uttroside B in liver cancer patients and technology transfer carried out with a multi-national company, Q Biomed. She has more than 45 publications and has been invited as a resource person to many national and international conferences. She is the editorial board member and reviewer of high-impact scientific journals. Her current research interest includes the study of signalling events associated with the fatty liver to Hepatocellular carcinoma, elucidating the role of plant-derived pure compounds in cancer chemoprevention, chemosensitization, and chemotherapy. She is also exploring the potential of traditional knowledge for various infectious diseases, their mechanism of action and validation through pre-clinical models.